p38 Inhibitors
Santa Cruz Biotechnology now offers a broad range of p38 Inhibitors. MAP (mitogen-activated protein) kinases play a significant role in many biological processes, including cell adhesion and spreading, cell differentiation and apoptosis. p38α, p38β and p38γ, also known as MAPK14, MAPK11 and MAPK12, respectively. p38 Inhibitors offered by Santa Cruz inhibit p38 and, in some cases, other signal transduction and cell proliferation related proteins. View detailed p38 Inhibitor specifications, including p38 Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 1 to 10 of 15 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(5Z)-7-Oxozeaenol | 253863-19-3 | sc-202055 sc-202055A | 1 mg 5 mg | $154.00 $633.00 | 13 | |
(5Z)-7-Oxozeaenol demonstrates a selective inhibition of p38 MAPK through its unique ability to engage in hydrogen bonding and π-π stacking interactions with key residues in the enzyme's active site. This compound's structural conformation allows for a stable complex formation, effectively disrupting the phosphorylation cascade. Its influence on the enzyme's allosteric regulation highlights its role in modulating downstream signaling events, showcasing a sophisticated mechanism of action. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK and suppresses its kinase activity by binding to the ATP-binding pocket of the protein. | ||||||
CAY10571 | 152121-46-5 | sc-223869 sc-223869A | 5 mg 10 mg | $56.00 $140.00 | ||
CAY10571 exhibits a distinctive mechanism of action as a p38 MAPK inhibitor, characterized by its ability to form strong electrostatic interactions with the enzyme's active site. This compound's unique steric configuration facilitates the disruption of critical protein-protein interactions, altering the enzyme's conformational dynamics. Additionally, its kinetic profile suggests a rapid onset of inhibition, underscoring its potential to modulate cellular signaling pathways effectively. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $86.00 $153.00 $275.00 $452.00 | 3 | |
PD169316 is a selective p38 MAPK inhibitor that blocks its activity, potentially suppressing downstream signaling events. | ||||||
LY2228820 | 862507-23-1 | sc-364525 | 5 mg | $191.00 | 1 | |
LY2228820 is a potent and selective inhibitor of p38 MAPK which inhibits its kinase activity. | ||||||
SKF 86002 | 72873-74-6 | sc-203265 | 5 mg | $153.00 | ||
SKF 86002 functions as a selective p38 MAPK inhibitor, distinguished by its capacity to engage in specific hydrogen bonding with key residues in the enzyme's active site. This interaction not only stabilizes the inhibitor-enzyme complex but also induces conformational changes that hinder substrate access. The compound's unique hydrophobic regions enhance binding affinity, while its reaction kinetics reveal a prolonged inhibitory effect, impacting downstream signaling cascades. | ||||||
SB220025 | 165806-53-1 | sc-202804 | 500 µg | $352.00 | ||
SB220025 acts as a selective p38 MAPK inhibitor, characterized by its ability to form strong electrostatic interactions with critical amino acid residues within the enzyme's active site. This binding promotes a unique conformational shift that obstructs substrate entry. Additionally, the compound's distinct steric properties contribute to its high specificity, while its kinetic profile indicates a rapid onset of inhibition, effectively modulating cellular signaling pathways. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
Doramapimod is a dual inhibitor of p38 MAPK and JNK, leading to a suppression of the p38 MAPK signaling pathway. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745 specifically targets p38 MAPK and inhibits its enzymatic activity, potentially suppressing its expression and function. | ||||||
CGH 2466 | 1177618-54-0 | sc-203541 sc-203541A | 10 mg 50 mg | $132.00 $559.00 | ||
CGH 2466 is a potent p38 MAPK inhibitor, distinguished by its unique ability to engage in hydrogen bonding with key residues in the enzyme's active site. This interaction stabilizes a specific conformation that hinders substrate access. The compound exhibits a favorable lipophilicity, enhancing its membrane permeability. Its reaction kinetics reveal a slow dissociation rate, allowing for sustained inhibition and prolonged modulation of downstream signaling cascades. | ||||||